- Home
- CRBP vs JRVR Comparison
CRBP vs JRVR Comparison
Compare CRBP & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | JRVR |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 209.9M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CRBP | JRVR |
|---|---|---|
| Price | $9.05 | $4.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $45.50 | $7.33 |
| AVG Volume (30 Days) | ★ 419.1K | 349.7K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.64% |
| EPS Growth | N/A | ★ 125.82 |
| EPS | N/A | ★ N/A |
| Revenue | $4,822,272.00 | ★ $687,614,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $116.00 | $1.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $7.12 | $3.76 |
| 52 Week High | $20.56 | $7.20 |
Technical Indicators
Market Signals| Indicator | CRBP | JRVR |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 54.87 |
| Support Level | $7.86 | $4.38 |
| Resistance Level | $9.73 | $4.69 |
| Average True Range (ATR) | 0.44 | 0.14 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 61.59 | 51.61 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.